Pre-market Mar 2026: 4564.T OncoTherapy Science JPX JPY 23.00 +4.55%: heavy flow

Pre-market trading shows 4564.T stock at JPY 23.00, up 4.55% on heavy volume on Mar 2026. We see unusually high activity with 66,792,100 shares traded versus an average of 40,752,247, flagging retail and institutional interest. The move follows no single press release, suggesting trade flow tied to trial milestones and technical momentum. We focus on liquidity, valuation, and catalysts to explain why OncoTherapy Science, Inc. (4564.T) is among Japan’s most active pre-market names.

Pre-market snapshot and trade triggers for 4564.T stock

Price opened at JPY 23.00 and traded between JPY 22.00 and JPY 23.00 during early pre-market. Volume is 66,792,100, or 1.76x relative volume, concentrating attention on JPX-listed OncoTherapy Science. The price sits near the 200-day average of JPY 23.91, and well above the 50-day average of JPY 20.94, indicating buyers cleared the shorter-term resistance.

Why volume surged and what traders watch

There is no single regulatory announcement, so the surge likely reflects positioning ahead of clinical updates and the May earnings date. Traders often front-run Phase III or pipeline news in biotech, which increases liquidity and intraday volatility. Watch institutional block trades and order-book depth for confirmation of sustained interest.

4564.T stock fundamentals and valuation

OncoTherapy Science reports EPS -2.83 and a negative PE of -8.13, reflecting ongoing R&D spending. Cash per share is JPY 6.06 and book value per share is JPY 5.93, producing a price-to-book of 3.88. Market capitalization is JPY 7,903,802,777 and the company invests about 65.79% of revenue into R&D, consistent with biotech peers in Healthcare.

Technical outlook for 4564.T stock

Momentum indicators show short-term strength: RSI 69.27 and MACD histogram 0.24 point to bullish bias but near overbought. CCI at 214.04 and MFI 82.57 warn of short-term exhaustion. Support sits near JPY 20.94 (50-day MA) and resistance near the year high JPY 35.00. Traders should expect volatility with an ATR of JPY 1.42.

Meyka AI rates 4564.T with a score out of 100

Meyka AI rates 4564.T with a score of 69.41 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, industry metrics, financial growth, key ratios, forecasts, and analyst consensus. Note independent company ratings also show mixed signals, with some sell-oriented metrics on profitability and valuation.

Risks, catalysts and sector context

Key catalysts are clinical trial readouts, licensing deals, and the May earnings announcement on 2026-05-11. Main risks include continued operating losses, negative EPS, and valuation gaps versus larger healthcare peers. Compared with Japan’s Healthcare sector, OncoTherapy’s price-to-book is higher than the sector average, reflecting biotech premium but greater binary risk.

Final Thoughts

We view 4564.T stock as an active pre-market mover driven by heavy volume and biotech-specific catalysts. At JPY 23.00, the shares trade above the 50-day average and show short-term momentum, but technical oscillators are near overbought levels. Meyka AI’s forecast model projects a one-year target of JPY 17.31, implying an expected downside of -24.80% versus the current price. The monthly model at JPY 16.61 implies -27.78% downside. These model projections are data-driven scenarios and not guarantees. For traders, the current setup offers high liquidity and clear stop levels, while investors should weigh patent, trial, and cash runway risks. We use Meyka AI as an AI-powered market analysis platform to combine technical, fundamental, and forecast data for clarity on possible paths for OncoTherapy Science, Inc.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.